Shorter TB treatment for children
Treatments studied
Part of Infections clinical trials.
This study is testing whether a shorter course of TB medicine works just as well as the standard longer treatment for children with drug-susceptible tuberculosis. It aims to make treatment easier for families.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 3 months and 10 years old.
- Your child's weight must be at least 6.6 pounds (3 kg) and less than 99 pounds (45 kg).
- Your child must have tuberculosis (TB) in the chest or certain other parts of the body, and it must be the kind that can be treated with standard medicines (not drug-resistant).
- If your child has HIV, they must be taking a specific HIV medicine called dolutegravir.
- Your child must not have started TB treatment for more than 5 days before joining.
- Your child must not have severe TB forms like TB meningitis, bone/joint TB, or miliary TB.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This trial tests a shorter treatment regimen for people with tuberculosis (TB) who don't have symptoms. If you have TB bacteria in your lungs but no cough, fever, night sweats, or weight loss, this study may offer a more convenient treatment option.
This study tests a shorter, all-oral treatment for people with Rifampicin-resistant TB. It aims to see if a new combination of drugs works well and safely over a shorter time.
This study tests a daily combination of two medicines, rifapentine and isoniazid (called 1HP), to prevent tuberculosis (TB) in children under 13 years old. It includes children who have been exposed to TB or are at high risk, both those living with HIV and those without HIV.
This trial tests whether a shorter, rifampicin-based treatment works well for people with less severe TB in the lungs. If you have limited TB that is sensitive to rifampicin, you might be able to take medicine for a shorter time than usual.
This trial tests if a shorter treatment course works as well as the standard one for people whose chest X-rays suggest TB but whose sputum tests are negative. It aims to make treatment easier for patients.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.